Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Lipids, lipid compositions, and methods of using them

a technology of lipid compositions and lipid compounds, applied in the direction of drug compositions, peptide/protein ingredients, antibody medical ingredients, etc., can solve the problems of high trafficking of biologically active agents into living cells, affecting the delivery of biologically active agents to subjects, and increasing the risk of toxic effects and side effects

Inactive Publication Date: 2011-08-18
NOVARTIS AG
View PDF17 Cites 256 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0418]The compounds, compositions, methods and uses may involve administration conditions suitable for reducing or inhibiting, or ameliorating a disease or disorder. In one embodiment, a therapeutically effective amount of an RNAi agent is administered to a patient in need thereof, wherein the level of target gene expression is reduced in the patient compared to an untreated patient.
[0419]In one embodiment, the expression of a target gene implicated in the disease or condition of interest is reduced by about 10%, more preferably about 20%, more preferably about 30%, more preferably about 40%, more preferably about 50%, more preferably about 60%, more preferably about 70%, more preferably about 80%, more preferably about 90%, more preferably about 95%, more preferably about 98%, and most preferably about 100% relative to an untreated patient.

Problems solved by technology

The delivery of biologically active agents (including therapeutically relevant compounds) to subjects is often hindered by difficulties in the compounds reaching the target cell or tissue.
In particular, the trafficking of many biologically active agents into living cells is highly restricted by the complex membrane systems of the cells.
These restrictions can result in the need to use much higher concentrations of biologically active agents than is desirable to achieve a result, which increases the risk of toxic effects and side effects.
One class of biologically active agents that is particularly difficult to deliver to cells is a biotherapeutic (including nucleosides, nucleotides, polynucleotides, nucleic acids and derivatives).
Viral vectors can be used to transfer genes efficiently into some cell types, but they generally cannot be used to introduce chemically synthesized molecules into cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipids, lipid compositions, and methods of using them
  • Lipids, lipid compositions, and methods of using them
  • Lipids, lipid compositions, and methods of using them

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0640]Linoleyl alcohol (48.7 g, 183 mmol) is added to a round bottom flask and dissolve in THF (400 mL). The resulting solution is cooled using an ice bath and sodium hydride (13.16 g, 329 mmol) is added. The resulting slurry is stirred for 1 h at rt. Epibromohydrin is added in one portion and the reaction is continued at rt. After 4 h stirring, additional sodium hydride (13.16 g, 329 mmol) is added. After an additional h stirring at rt, another aliquot of epibromohydrin (32.5 g, 238 mmol) is added. The reaction is then heated to 50° C. overnight. The reaction is then cooled to rt and quenched with water. EtOAc is added and the resulting organic layer collected, washed with brine and dried over sodium sulfate. The volatiles are removed by rotary evaporation and the resulting residue purified by chromatography on silica in EtOAc / heptanes to yield the desired epoxide.

Cholesterol Tosylate

example 2

[0641]Cholesterol (50 g, 129 mmol) is dissolved in DCM (55 mL) and pyridine (150 mL). The resulting solution is cooled to 0° C. and tosyl chloride is added in one portion as a solid. The reaction is allowed to slowly warm to rt overnight. The reaction is concentrated by rotary evaporation and MeOH (500 mL) is added to produce a white solid. Stirring is continued for 30 min and the precipitate collected by filtration, washed with MeOH and dried under vacuum to yield the desired tosylate.

Cholesterol Diglycol

example 3

[0642]Cholesterol tosylate (73 g, 128 mmol) is dissolved in 1,4-dioxane (750 mL). Diethylene glycol (294 mL, 3077 mmol) is added and the reaction is heated to a gentle reflux overnight. The resulting solution is cooled to rt and concentrated by rotary evaporation. The resulting gel is taken up in DCM and stirred with water. The resulting organic layer is collected and the aqueous layer extracted once with DCM. The organic layers are combined, dried over sodium sulfate, and concentrated by rotary evaporation. The crude product is purified on silica in EtOAc / heptane to yield the desired cholesterol diglycol.

Cholesterol Diglycol Tosylate

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pKaaaaaaaaaaa
pKaaaaaaaaaaa
pKaaaaaaaaaaa
Login to View More

Abstract

Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and / or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I).The invention also relates to compositions and uses for stealth lipids of formula (XI).Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and / or tissues.

Description

[0001]This application claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application 61 / 284,787, filed 23 Dec. 2009, the contents of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention relates to cationic lipid compounds, stealth lipid compounds and to compositions comprising such compounds. The invention also relates to processes for making such compounds and compositions, and to methods and uses of such compounds and compositions, e.g., to deliver biologically active agents to cells and tissues. The invention describes optimized pKa ranges for cationic lipids for use in lipid formulations to deliver biologically active agents to specific cell types, including especially liver and tumors, and methods for optimizing the formulations.BACKGROUND TO THE INVENTION[0003]The delivery of biologically active agents (including therapeutically relevant compounds) to subjects is often hindered by difficulties in the compounds reachin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K47/06C07J43/00A61P35/00A61K47/28C07D303/24C07C43/178C07C271/16A61K31/575A61K38/02A61K31/7088A61K38/43
CPCA61K9/1272A61K31/7088A61K47/10A61K47/18A61K47/28A61K47/30A61K2300/00A61P1/16A61P35/00A61P43/00C07J9/00C07J31/006C07J41/0055C07J43/003A61K9/127A61K47/14
Inventor BARYZA, JEREMYBOWMAN, KEITHGEALL, ANDREWLABONTE, TANZINALEE, CAMERONVARGEESE, CHANDRAWEST, LAURAZHAO, JUNPING
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products